20
Participants
Start Date
September 30, 2024
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection
Stop Treatment with Bulevertide in patients with compensated liver disease and chronic HDV infection who have been treated for at least 48 weeks and reached HDV RNA below 100 IU/ml for at least 24 weeks.
RECRUITING
Charité - University Hospital Berlin (Campus Virchow-Clinic); Department of Hepatology and Gastroenterology, Berlin
RECRUITING
Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico; Division of Gastroenterology and Hepatology, Milan
RECRUITING
Hannover Medical School; Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hanover
RECRUITING
University Hospital Frankfurt; Medical Clinic 1, Frankfurt am Main
RECRUITING
University Hospital Heidelberg; Department of Internal Medicine IV: Gastroenterology, Hepatology, Infectious Diseases, Poisoning, Heidelberg
German Liver Foundation (DLS)
UNKNOWN
HepNet Study House, German Liverfoundation
NETWORK
Hannover Medical School
OTHER